BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...Global Investors and Wellington Management Co.TARGETSROR1 - Receptor tyrosine kinase-like orphan receptor 1 Paul Bonanos Merck & Co. Inc. VelosBio Inc. Receptor tyrosine kinase-like...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

...as the degree of cartilage structural damage, as measured by clinical disease scores and histology.TARGET/MARKER/PATHWAY: Receptor tyrosine kinase-like...
...University of London, London, U.K.email: asthorup@gmail.com CONTACT: Francesco Dell’Accio, same affiliation as aboveemail: fdellaccio@gmail.com Claire Quang Queen Mary University of London Receptor tyrosine kinase-like...
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

...Asabys Partners with participation by existing investors Novator and Frumtak Ventures.TARGETSIL-7R - Interleukin-7 receptorROR1 – Receptor tyrosine kinase-like...
BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

...cancer driven by allosteric EGFR or HER2 mutations. The company presented the data for the receptor tyrosine kinase...
BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...months (see “Biggest SPAC Merger Yet”).TARGETSHGF/SF - Hepatocyte growth factor/scatter factorMET (c-MET; HGFR) - c-Met receptor tyrosine kinase Paul...
BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

...Phase II study of the candidate in a similar patient population. TARGETSHER3 (ERBB3; EGFR3) – Erb-b2 receptor tyrosine kinase...
BioCentury | Sep 4, 2020
Product Development

Rain to advance growing precision oncology pipeline with $63M series B

...factor receptor 2 HER3 (ERBB3; EGFR3) – Erb-b2 receptor tyrosine kinase...
...factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Erb-b2 receptor tyrosine kinase...
BioCentury | Aug 28, 2020
Product Development

Aug. 27 Quick Takes: Priority Review for casimersen in DMD, tepotinib in NSCLC; plus asciminib meets in CML and a farewell to digital pioneer Proteus

...Phase III trials to treat plaque psoriasis.TARGETSAHR - Aryl hydrocarbon receptorc-MET (MET; HGFR) - c-Met receptor tyrosine kinase BC...
BioCentury | Aug 21, 2020
Product Development

Basket trials carry tumor-agnostic drug development forward

...11 biomarker-defined subpopulations.TARGETSc-MET (MET; HGFR) – c-Met receptor tyrosine kinase EGFR...
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...once the COVID-19 pandemic subsides.TARGETSNTRK (Trk) - Neurotrophic tyrosine kinase receptorROS1 - c-ros proto-oncogene 1 receptor tyrosine kinase BC...
Items per page:
1 - 10 of 1631